Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Bispecific Antibodies
    • 1.4.3 Antibody Drug Conjugates
    • 1.4.4 Chimeric Antigen Receptor T-Cells
  • 1.5 Market by Application
    • 1.5.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application: 2020 VS 2026
    • 1.5.2 Liver Cancer
    • 1.5.3 Respiratory Cancer
    • 1.5.4 Brain Cancer
    • 1.5.5 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry
      • 1.6.1.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and B-Cell Maturation Antigen(BCMA) Targeted Therapies Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for B-Cell Maturation Antigen(BCMA) Targeted Therapies Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Perspective (2015-2026)
  • 2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Growth Trends by Regions
    • 2.2.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Share by Regions (2015-2020)
    • 2.2.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Growth Strategy
    • 2.3.6 Primary Interviews with Key B-Cell Maturation Antigen(BCMA) Targeted Therapies Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Market Size
    • 3.1.1 Global Top B-Cell Maturation Antigen(BCMA) Targeted Therapies Players by Revenue (2015-2020)
    • 3.1.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Ratio
    • 3.2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue in 2019
  • 3.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players Head office and Area Served
  • 3.4 Key Players B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Solution and Service
  • 3.5 Date of Enter into B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Type (2015-2020)
  • 4.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Type (2021-2026)

5 B-Cell Maturation Antigen(BCMA) Targeted Therapies Breakdown Data by Application (2015-2026)

  • 5.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)
  • 5.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 6.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in North America (2019-2020)
  • 6.3 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 6.4 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 7.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in Europe (2019-2020)
  • 7.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 7.4 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

8 China

  • 8.1 China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 8.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in China (2019-2020)
  • 8.3 China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 8.4 China B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 9.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in Japan (2019-2020)
  • 9.3 Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 9.4 Japan B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 10.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 10.4 Southeast Asia B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

11 India

  • 11.1 India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 11.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in India (2019-2020)
  • 11.3 India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 11.4 India B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2015-2020)
  • 12.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type (2015-2020)
  • 12.4 Central & South America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Transposagen Biopharmaceuticals
    • 13.1.1 Transposagen Biopharmaceuticals Company Details
    • 13.1.2 Transposagen Biopharmaceuticals Business Overview and Its Total Revenue
    • 13.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020))
    • 13.1.5 Transposagen Biopharmaceuticals Recent Development
  • 13.2 Sutro Biopharma
    • 13.2.1 Sutro Biopharma Company Details
    • 13.2.2 Sutro Biopharma Business Overview and Its Total Revenue
    • 13.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.2.5 Sutro Biopharma Recent Development
  • 13.3 Malin Corporation
    • 13.3.1 Malin Corporation Company Details
    • 13.3.2 Malin Corporation Business Overview and Its Total Revenue
    • 13.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.3.5 Malin Corporation Recent Development
  • 13.4 Eureka Therapeutics
    • 13.4.1 Eureka Therapeutics Company Details
    • 13.4.2 Eureka Therapeutics Business Overview and Its Total Revenue
    • 13.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.4.5 Eureka Therapeutics Recent Development
  • 13.5 firstVentury Equity
    • 13.5.1 firstVentury Equity Company Details
    • 13.5.2 firstVentury Equity Business Overview and Its Total Revenue
    • 13.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.5.5 firstVentury Equity Recent Development
  • 13.6 Five Prime Therapeutics
    • 13.6.1 Five Prime Therapeutics Company Details
    • 13.6.2 Five Prime Therapeutics Business Overview and Its Total Revenue
    • 13.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.6.5 Five Prime Therapeutics Recent Development
  • 13.7 Credit Suisse Securities
    • 13.7.1 Credit Suisse Securities Company Details
    • 13.7.2 Credit Suisse Securities Business Overview and Its Total Revenue
    • 13.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.7.5 Credit Suisse Securities Recent Development
  • 13.8 Dana-Farber Cancer Institute
    • 13.8.1 Dana-Farber Cancer Institute Company Details
    • 13.8.2 Dana-Farber Cancer Institute Business Overview and Its Total Revenue
    • 13.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.8.5 Dana-Farber Cancer Institute Recent Development
  • 13.9 Deerfield Partners
    • 13.9.1 Deerfield Partners Company Details
    • 13.9.2 Deerfield Partners Business Overview and Its Total Revenue
    • 13.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.9.5 Deerfield Partners Recent Development
  • 13.10 Onyx Pharmaceuticals
    • 13.10.1 Onyx Pharmaceuticals Company Details
    • 13.10.2 Onyx Pharmaceuticals Business Overview and Its Total Revenue
    • 13.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 13.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 13.10.5 Onyx Pharmaceuticals Recent Development
  • 13.11 Juno Therapeutics
    • 10.11.1 Juno Therapeutics Company Details
    • 10.11.2 Juno Therapeutics Business Overview and Its Total Revenue
    • 10.11.3 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Introduction
    • 10.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies Business (2015-2020)
    • 10.11.5 Juno Therapeutics Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global B-Cell Maturation Antigen(BCMA) Targeted Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the B-Cell Maturation Antigen(BCMA) Targeted Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Transposagen Biopharmaceuticals
    Sutro Biopharma
    Malin Corporation
    Eureka Therapeutics
    firstVentury Equity
    Five Prime Therapeutics
    Credit Suisse Securities
    Dana-Farber Cancer Institute
    Deerfield Partners
    Onyx Pharmaceuticals
    Juno Therapeutics

    Market segment by Type, the product can be split into
    Bispecific Antibodies
    Antibody Drug Conjugates
    Chimeric Antigen Receptor T-Cells
    Market segment by Application, split into
    Liver Cancer
    Respiratory Cancer
    Brain Cancer
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global B-Cell Maturation Antigen(BCMA) Targeted Therapies status, future forecast, growth opportunity, key market and key players.
    To present the B-Cell Maturation Antigen(BCMA) Targeted Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of B-Cell Maturation Antigen(BCMA) Targeted Therapies are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now